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Abstract 
Background: The long‑term effects of psychotropic drugs are associated with the reversal of disease‑related altera‑
tions through the reorganization and normalization of neuronal connections. Molecular factors that trigger drug‑
induced brain plasticity remain only partly understood. Doublecortin‑like kinase 1 (Dclk1) possesses microtubule‑
polymerizing activity during synaptic plasticity and neurogenesis. However, the Dclk1 gene shows a complex profile 
of transcriptional regulation, with two alternative promoters and exon splicing patterns that suggest the expression of 
multiple isoforms with different kinase activities.
Results: Here, we applied next‑generation sequencing to analyze changes in the expression of Dclk1 gene isoforms 
in the brain in response to several psychoactive drugs with diverse pharmacological mechanisms of action. We used 
bioinformatics tools to define the range and levels of Dclk1 transcriptional regulation in the mouse nucleus accum‑
bens and prefrontal cortex. We also sought to investigate the presence of DCLK1‑derived peptides using mass spec‑
trometry. We detected 15 transcripts expressed from the Dclk1 locus (FPKM > 1), including 2 drug‑regulated variants 
(fold change > 2). Drugs that act on serotonin receptors (5‑HT2A/C) regulate a subset of Dclk1 isoforms in a brain‑
region‑specific manner. The strongest influence was observed for the mianserin‑induced expression of an isoform 
with intron retention. The drug‑activated expression of novel alternative Dclk1 isoforms was validated using qPCR. The 
drug‑regulated isoform contains genetic variants of DCLK1 that have been previously associated with schizophrenia 
and hyperactivity disorder in humans. We identified a short peptide that might originate from the novel DCLK1 pro‑
tein product. Moreover, protein domains encoded by the regulated variant indicate their potential involvement in the 
negative regulation of the canonical DCLK1 protein.
Conclusions: In summary, we identified novel isoforms of the neuroplasticity‑related gene Dclk1 that are expressed 
in the brain in response to psychotropic drug treatments.
Keywords: Dclk1, Alternative transcription, Psychotropic drugs, Nucleus accumbens, Prefrontal cortex
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
BMC Neuroscience
*Correspondence:  michkor@if‑pan.krakow.pl 
1 Department of Molecular Neuropharmacology, Institute 
of Pharmacology of the Polish Academy of Sciences, Smetna 12, 
31‑343 Krakow, Poland
Full list of author information is available at the end of the article
Page 2 of 14Zygmunt et al. BMC Neurosci  (2018) 19:55 
Background
Psychiatric disorders are associated with complex pat-
terns of abnormal neuronal activity and maladaptive 
plasticity [1]. Treatment with psychotropic drugs aims 
to restore the normal function of the affected circuits; 
long-term therapeutic benefits may depend on the abil-
ity of drugs to restore normal plasticity. Consistent with 
this notion, commonly used psychotropic drugs robustly 
induce molecular effects on the brain associated with 
neuroplastic alterations [2, 3].
The dynamic process of cytoskeletal reorganization is 
one of the key components of brain plasticity [4]. Based 
on findings from rodent studies, the canonical Dclk1 
transcript encodes a protein that mediates microtubule 
polymerization and is involved in neurogenesis and neu-
ronal plasticity by regulating dendritic outgrowth and 
synapse formation [5]. This gene is widely expressed in 
the nervous system and has been reported to show per-
sistent expression in adult neurons [6]. Moreover, genetic 
variants of DCLK1 are associated with psychiatric dis-
orders in humans [7, 8]. These observations suggest a 
potential role for Dclk1 in the formation of drug-induc-
ible changes in the brain.
The Dclk1 gene consists of 20 exons that undergo alter-
native splicing, resulting in several known variants [6, 9, 
10]. Previously identified Dclk1 transcripts include both 
mRNAs coding for distinct proteins and noncoding, 
regulatory RNAs. The multiple isoforms of this gene are 
differentially expressed and have different kinase activi-
ties [6, 11]. The isoforms are classified into four groups 
expressed from the following two distinct promoters: 
the full-length variant (containing both DCX and kinase 
domains), a kinase-lacking isoform (DCL), a double-
cortin-lacking isoform (CPG16) and the CaMK-related 
peptide (CARP/Ania-4) lacking both DCX and kinase 
domains. The mechanism involved in transcriptional 
regulation of the diverse alternatively spliced variants of 
Dclk1 remains elusive. The importance of the expression 
of alternatively spliced gene products from a single gene 
locus in brain physiology and disease progression has 
been reported [10, 12]. Therefore, acquiring gene expres-
sion profiles from all gene variants is a necessary first 
step in understanding the specific functions of proteins 
and identification of disease-relevant isoforms.
Here, we investigate drug-induced alternative tran-
scription from the Dclk1 locus. We used next-generation 
sequencing to map all transcripts of the Dclk1 gene, both 
currently annotated in the mouse genome as well as 
putative novel RNAs. We found that the gene expression 
patterns are both drug- and brain-region-specific. More-
over, we identified a new Dclk1 variant that is specifically 




Adult male (8–10  weeks old) C57BL/6N mice (Charles 
River Laboratories, Wilmington, Massachusetts, USA) 
were housed in Plexiglas cages (Type II L, 2–5 animals 
per cage) containing Aspen Laboratory bedding (MIDI 
LTE E-002, Abedd) in a conventional facility on a 12  h 
light/dark cycle with ad  libitum access to water and 
chow (RM1 A (P), Special Diets Services) and an ambi-
ent temperature of 22 ± 2  °C. All the experiments were 
conducted in accordance with the European Union 
guidelines for the care and use of laboratory animals 
(2010/63/EU). Experimental protocols were reviewed 
and approved by the 2nd Local Institutional Animal Care 
and Use Committee (IACUC), Institute of Pharmacology 
Polish Academy of Sciences in Kraków (permit number: 
1156/2015).
Drug treatment
Mice received a single intraperitoneal injection (vol. 
10 ml/kg) of haloperidol (1 mg/kg), risperidone (0.5 mg/
kg), methamphetamine (2  mg/kg), venlafaxine (16  mg/
kg), mianserin (20  mg/kg) or ketamine (20  mg/kg) dis-
solved in saline, or saline with a drop of 0.1 M HCl in the 
case of haloperidol and risperidone. Regarding peptide 
analyses, mice were injected with mianserin (20  mg/kg) 
daily over 5 days. All animals were decapitated 2 h after 
treatment, and brains were then extracted and dissected 
with needles under a binocular. Drug doses that pro-
duce robust and comparable gene expression alterations 
were selected based on our previous experience [2, 3, 13]. 
Doses were selected to provide a reasonable compari-
son of the effects of each drug on the molecular level. All 
of the drugs were shown to cross the blood–brain bar-
rier [14] and accumulate in the brain within minutes of 
administration [15–18].
Tissue collection and RNA isolation
Tissue extraction was performed as described previously 
[3, 13]. Briefly, whole brains were incubated in RNAl-
ater reagent (Ambion) overnight and then coronally sec-
tioned into 125 μm slices using a Vibratome (Leica). The 
prefrontal cortex (PFCx) and nucleus accumbens (NAc) 
were dissected with needles under a binocular micro-
scope with a Paxinos atlas as a Ref. [19]. The cingulate, 
prelimbic, infralimbic and part of the dorsal peduncu-
lar cortex were collected from the area approximately 
+ 1.90 to + 1.15 mm from the bregma. The shapes of the 
corpus callosum and anterior commissure were used to 
assess the distance from the bregma. Tissue samples were 
placed in RNAlater reagent and preserved at − 70  °C. 
The samples were homogenized in 1  ml of TRIzol rea-
gent (Invitrogen, Carlsbad, CA, USA). RNA was isolated 
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according to the manufacturer’s protocol and was further 
purified using the RNeasy Mini Kit (Qiagen Inc.). The 
RNA quality was determined using an Agilent 2100 Bio-
analyzer (Agilent, Palo Alto, CA, USA).
Microarray data analysis
In this study, we reanalyzed our previously published 
microarray data for striatal gene expression profiles pro-
duced by 18 major psychoactive drugs at 1, 2, 4 and 8 h 
after acute administration (Please see: [2] for details). 
Briefly, the analysis and quality control of 324 micro-
arrays were performed using the BeadArray R pack-
age v1.10.0. After background subtraction, data were 
normalized using quantile normalization and then 
 log2-transformed. The results were standardized to 
reduce the effects of hybridization batches using z-score 
transformation. Genes2mind was used to visualize the 
results (http://genes 2mind .org) [20].
Whole‑transcriptome sequencing
The procedure was performed as described previously 
[3, 13]. Total RNA (1  μg) was ribo-depleted using the 
RiboMinus Eukaryote Kit v2 (Ambion). rRNA-depleted 
RNA was used to prepare the RNA-seq library gener-
ated using the Ion Total RNA-seq Kit v2. Templates were 
prepared using emulsion PCR (ePCR) with the Ion One-
Touch™ 2 Instrument and the Ion PI™ Template OT2 
200 Kit v3. Sequencing was performed using an Ion PI™ 
Sequencing 200 Kit v3 and the Ion PI™ Chip v2 (Life 
Technologies). The template-positive ion sphere parti-
cles (ISPs) were loaded onto an Ion PITM Chip v2 and 
sequenced (single end reads > 100 bp).
NGS data analysis
The quality of the NGS data was assessed using FastQC. 
The RNA-seq reads were aligned using TopHat 2.0.1 fol-
lowed by Tmap 3.0.2. The transcript FPKM (Fragments 
Per Kilobase of transcript per Million fragments mapped) 
levels were quantified using Cufflinks v2.2.1 and GTF 
from the Ensembl gene database. Statistical significance 
was tested using ANOVA on  log2(1 + x) values [3]. The 
false discovery rate (FDR) was estimated using the Ben-
jamini–Hochberg method. All statistical analyses were 
performed using R software v3.3.1. Transcript annota-
tion and classification were performed using the BioMart 
interface to the Ensembl database. Identification of tran-
scription factor binding sites in the promoter regions 
corresponding to the identified transcripts was per-
formed using the seqinspector (seqinspector.cremag.org) 
[20]. The data stored in seqinspector included ENCODE 
ChIP-seq tracks and data deposited in the Gene Expres-
sion Omnibus (GEO).
Variant identification
Initial analysis of transcripts from the Dclk1 locus was 
based on GRCm38.p5/mm10, which lists 15 variants. A 
new variant was identified in the mouse NAc after mian-
serin treatment using Cufflinks. The new transcript was 
selected based on the abundance level (FPKM) calculated 
by Cufflinks; selection criteria were F (min-isoform-
fraction) = 0.005 and j (pre-mRNA-fraction) = 0.15. The 
depth parameter for each nucleotide of the Dclk1 tran-
script was computed using Samtools depth v0.1.19. The 
abundance levels for intron regions were calculated as 
the median read coverage of the intron.
Quantitative PCR
Reverse transcription was performed with the Omnis-
cript Reverse Transcriptase (Qiagen Inc.). qPCR was 
performed using TaqMan Gene Expression Assays 
(“probe 1”: Mm00444950_m1—exons 4–5 of Dclk1; 
“probe 2”: Mm01545304_m1—exons 6–7 of Dcl; “probe 
5”: Mm01512375_m1—exons 13–14 of Cpg16; “probe 3”: 
custom designed for 5′ intron 6 of Dclk1 using Custom 
TaqMan Assay Design Tool, assay ID: AJ20T2J, “probe 
4”: custom designed for 3′ intron 6 of Dclk1, assay ID: 
AI0IY5 V). The reactions were run on the CFX96 Real-
Time system (Bio-Rad). Each template was generated 
from an individual animal. Expression of the hypox-
anthine–guanine phosphoribosyltransferase 1 (Hprt1) 
transcript was used to control for variations in cDNA 
concentrations. The abundance of each RNA was cal-
culated as  2−(threshold cycle). The data were analyzed using 
one-way analysis of variance (ANOVA) followed by Tuk-
ey’s HSD.
Protein isolation
For the proteomics assessment, NAc samples were col-
lected after 5  days of mianserin treatment. Immedi-
ately after removal, the tissue was homogenized in 1% 
SDS using the Rotor Stator Homogenizer  (IKA®-Werke, 
Staufen, Germany) and cleared by centrifugation (16,000g 
for 3 min). The protein concentration in the supernatant 
was determined using the BCA Protein Assay Kit (Sigma-
Aldrich). Samples containing 50  μg of protein were 
heated in Laemmli 6 × loading buffer for 5 min at 95  °C 
and resolved by sodium dodecyl sulphate–polyacryla-
mide gel electrophoresis (SDS-PAGE; 18% Criterion™ 
TGX™ Precast Gels, Bio-Rad). After electrophoresis, the 
gel was transferred to 40% methanol/20% acetic acid and 
stained with Coomassie brilliant blue R250 overnight. 
Bands corresponding to the < 10 kD fraction of peptides 
according to the Polypeptide 1.4–26.6 kD SDS-PAGE 
Standard (Bio-Rad, #1610326) were excised from the gel.
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LC–MS/MS analysis
The procedure is based on a previously reported proto-
col [21]. First, we injected the heavy-labeled peptide for 
shotgun LC–MS/MS analysis at 1  pmol. Peptide reten-
tion time was determined and a spectral library was 
constructed in Skyline software version 3.7. Then, the 
peptide was measured using the scheduled parallel reac-
tion monitoring (PRM) mode. At 10 fmol per injection 
no contamination with light counterparts was observed.
The gel band was alternately washed with 25% ace-
tonitrile (ACN)/25  mM  (NH4)HCO3 (ABC) and 50% 
ACN/25 mM ABC, dehydrated with 100% ACN and then 
air dried. Then, the band was re-swelled in 25 mM ABC 
containing endoproteinase LysC (Promega) and digested 
overnight at 37 °C. The reaction was stopped by addition 
of  CF3COOH (TFA), and peptides were collected, vac-
uum dried and resuspended in the solution containing 
heavy-labeled peptide.
The samples were analyzed using a Q-Exactive mass 
spectrometer (Thermo Scientific) coupled with nano-
HPLC (UltiMate 3000 RSLCnano System, Thermo 
Scientific). Peptides were loaded onto a trap column 
(AcclaimPepMap100 C18, Thermo Scientific; ID 75 μm, 
length 20  mm, particle size 3  μm, pore size 100 Å) 
in 2% ACN/0.05% TFA at a flow rate of 5  μl/min and 
then separated on an analytical column (AcclaimPep-
MapRLSC C18, Thermo Scientific; ID 75  μm, length 
500  mm, particle size 2  μm, pore size 100 Å) using a 
30  min gradient of ACN from 2 to 40% in the pres-
ence of 0.05% formic acid at a flow rate of 300 nl/min. 
A digital PicoView 550 ion source (New Objective) 
was used for ionization. Labeled peptide and its light 
counterpart were isolated in scheduled PRM with a 
2 m/z window and fragmented with a normalized col-
lision energy of 25. Resulting ions were collected with 
a maximum injection time of 500 ms and an automatic 
gain control (AGC) target value of 2.0 × 104. Measure-
ments were collected at a resolution of 140,000. Data 
were analyzed using Skyline software (version 3.7). The 
signal corresponding to the SPSPSPTSPGSLRK peptide 
was verified by confirming its coelution with the heavy-
labeled counterpart and by comparing the fragment ion 
area ratios in peptide pairs.
Results
Changes in Dclk1 expression in response to psychotropic 
drugs
First, we reexamined the expression of alternatively 
spliced transcripts from the Dclk1 locus based on the 
previously reported dataset describing the effects of 
various psychotropic drugs on the mouse striatum [2]. 
The results of the analysis are shown in Fig.  1. Panel 
A shows a schematic representation of the main tran-
scripts of the mouse Dclk1 gene based on the NCBI37/
mm9 mouse genome release. Regions correspond-
ing to probes from the MouseWG-6 v2 BeadChip are 
marked with blue or red symbols. Probes correspond 
to nonoverlapping transcripts and neither detected the 
full-length canonical Dclk1 transcript. As shown in the 
reanalysis of the array data presented in panel B, levels 
of transcripts detected by the probes were differentially 
affected by treatments with psychotropic drugs.
The mRNA levels measured using the first microarray 
probe (ILMN_1259689, presented as a red star in Fig. 1; 
drug P value = 4.14 × 10−16, time P-value = 9.9 × 10−15, 
interaction P-value = 4.2 × 10−5) indicated increased 
expression after the administration of mianserin (1, 2 
and 4 h after the injection), risperidone (1 and 2 h) and, 
to a lesser extent, haloperidol (2 h) treatments (Fig. 1b). 
The second probe (ILMN_2434274, blue star; drug 
P-value = 4.68 × 10−16, time P-value = 1.2 × 10−4, inter-
action P-value = 2.5 × 10−7) revealed a different pattern 
of regulation, with an increase in mRNA abundance 
levels 8 h after the tranylcypromine treatment. Analysis 
of the array profiling results showed isoform-specific 
regulation of Dclk1 expression by psychotropic drugs. 
However, the interpretation was also confounded by 
ambiguous detection of the Dclk1 transcripts.
(See figure on next page.)
Fig. 1 Schematic representation of the Dclk1 gene and psychotropic drug treatment‑mediated regulation of its expression. a Main transcripts of 
the Dclk1 locus: two Cpg16 variants (ENSMUST00000198437, ENSMUST00000070418), Carp (ENSMUST00000199585), intron‑retained isoform (RI, 
ENSMUST00000198757), Dcl (ENSMUST00000167204) and Dclk1 (ENSMUST00000054237). The positions of the microarray probes are indicated 
by the stars. The schematic was generated based on information in the Ensembl database and available literature [6, 26]. The functional protein 
domains are boxed (SP is the serine/proline‑rich domain). b Results from the microarray gene expression analysis are presented as time courses (1, 
2, 4 and 8 h) of fold changes in expression compared to levels observed in saline‑treated controls (as described in the legend). The measurements 
from two microarray probes are presented. The left side of the figure shows Dclk1 levels based on the ILMN_1259689 probe, whereas the right side 
corresponds to ILMN_2434274. The list of analyzed drugs include mianserin (MIA), imipramine (IMI), fluoxetine (FLU), bupropion (BUP), tianeptine 
(TIA), tranylcypromine (TRA), methamphetamine (MET), cocaine (COC), nicotine (NIC), heroin (HER), morphine (MOR), ethanol (ETO), diazepam (DIA), 
buspirone (BUS), hydroxyzine (HYD), clozapine (CLO), risperidone (RIS), haloperidol (HAL), saline (SAL), and naive (NAI) control. *P < 0.01, **P < 0.001, 
***P < 0.0001, one‑way ANOVA of the drug factor
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Transcriptome profiling of the effects of psychotropic 
drugs using RNA sequencing
We used next-generation sequencing to comprehen-
sively examine drug-induced Dclk1 gene expression at 
the level of specific transcriptional units. Sequencing 
was performed on ribo-depleted RNA samples derived 
from the mouse nucleus accumbens septi (NAc) and 
prefrontal cortex (PFCx) 2 h after treatment with anti-
depressants (venlafaxine and mianserin), antipsychotics 
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(haloperidol and risperidone), a psychostimulant 
(methamphetamine) or a psychotomimetic (ketamine).
We measured normalized transcript abundance levels 
(FPKM) for all transcripts annotated in the GRCm38.
p5 genome release using the Cufflinks package. A total 
of 110,327 different transcripts corresponding to 45,935 
annotated genes were detected in the PFCx or NAc at the 
threshold of a mean FPKM ≥ 0.1.
The overall differences in drug-induced gene expres-
sion between the NAc and PFCx were assessed using a 
one-way ANOVA for drug factor performed separately 
in each tissue. We found 90 transcripts regulated by the 
treatment only in the NAc and 246 transcripts altered 
in the PFC (at FDR < 0.0001). The examples of regulated 
genes are Map6 and Cdkn1a in the NAc, and Bhlhe40 
and Fkbp5 in the PFC. We also identified 26 transcripts 
regulated in both the analyzed tissues above the thresh-
old, including Homer1, Sgk1 and Fosb (Additional file 1: 
Figure S1).
Drug-regulated changes in transcript levels were clas-
sified by biotypes and alternatively spliced events. Nota-
bly, 78% of regulated transcripts in the NAc and 65% 
of the transcripts in the PFCx encoded proteins, com-
pared with 56% of the transcripts expressed in the NAc 
or PFCx under basal conditions (Additional file 2: Figure 
S2). Among the drug-induced alterations, an enrichment 
of protein-coding variants was observed, although the 
majority of noncoding, regulated transcripts were classi-
fied as intron-retained transcripts.
We used a two-way ANOVA with the drug and tissue 
as factors to identify drug-regulated changes in transcript 
levels (arbitrary cutoff at treatment effect FDR < 0.001; 
Additional file  3: Figure S3). Figure  2 shows the hierar-
chical clustering of the top 113 transcripts, grouped into 
four clusters. Transcripts from the four main branches 
were examined for overrepresented putative transcrip-
tion factor binding sites in their promoter regions using 
seqinspector [20].
Transcripts from the first pattern were upregulated by 
mianserin in both brain regions. Their expression also 
increased in the NAc in response to risperidone and halo-
peridol treatments. Examples of transcripts clustered in 
this group included Sgk1, Nfkbia and the long noncoding 
RNA Neat1. Promoters of these transcripts exhibit a sig-
nificant overrepresentation of the ChIP-seq signal for sev-
eral transcriptional factors, including GR (P = 9.7 × 10−6, 
t-test with Bonferroni’s correction, track GEO accession: 
GSM686976), E2F1 (P = 1.1 × 10−6, GSM881056) and 
NFKB1 (P = 1 × 10−5, GSM88115). Haloperidol, meth-
amphetamine and, to a lesser extent, risperidone induced 
the expression of the greatest number of transcripts (pat-
tern 2) in the NAc. The strongest induction in the PFCx 
was observed after methamphetamine treatment. Pattern 
2 included several genes involved in the molecular con-
trol of neuronal plasticity, such as Fosb, Arc, Junb or 
Homer1. The promoters of these transcripts contained a 
different set of putative transcriptional regulator binding 
sites, including SRF (P = 1.2 × 10−22, GSM530190) and 
EGR2 (P = 4.7 × 10−12, GSM881094). The expression of 
the third group of transcripts (pattern 3, e.g., Celf2 and 
Dclk1) was induced by mianserin, with stronger effects 
observed in the NAc. We only identified one overrepre-
sented potential transcriptional regulator of these genes, 
TBP (P = 3.5 × 10−7). The TBP binding motif was present 
in 18 of the 28 total genes. The Dclk1 transcript was clus-
tered into pattern 3. Notably, at the statistical threshold 
used to analyze the whole transcriptome, we observed 
significant changes in the levels of the transcript for only 
one Dclk1 isoform, a noncoding variant with a retained 
intron (ENSMUST00000198757). Finally, the expres-
sion of transcripts from pattern 4, including Clk1 and 
Hes5, decreased after mianserin treatment in both brain 
regions. Significantly overrepresented TFB sites were not 
present in the upstream promoter regions of transcripts 
from this cluster.
The profile of the drug-specific transcripts correspond-
ing to the Dclk1 locus was obtained by comparing the 
results of two high-throughput gene profiling methods-
microarray (Fig. 1) and RNA-sequencing (Fig. 2).
Isoform‑specific regulation of Dclk1 expression
Next, we performed a detailed analysis of the sequenc-
ing results mapped to the Dclk1 locus. Based on the 
assignments from Cufflinks using the GRCm38.p5 
mouse genome release, sequencing reads corresponded 
to 12 transcripts expressed from the Dclk1 locus (at 
FPKM > 1), with 8 highly abundant isoforms (FPKM > 5). 
Three isoforms were not detected in the NAc or PFCx 
(ENSMUST00000198821, ENSMUST00000197870, and 
ENSMUST00000196745). The majority of the sequencing 
reads corresponded to Carp (ENSMUST00000199585), 
Dcl (ENSMUST00000167204) and Cpg16 (ENS-
MUST00000198437). Two of the transcripts assembled 
by Cufflinks contained retained introns and had not 
previously been described (Additional file  4: Figure S4). 
Relative changes in the abundance of the transcripts are 
shown in Fig. 3.
The expression of the Carp transcript in the NAc 
was induced in response to mianserin  (log2FC = 1.78, 
P = 0.0002), risperidone  (log2FC = 1.07, P = 0.007) and 
venlafaxine  (log2FC = 1.01, P = 0.009). Carp expres-
sion in the PFCx was only regulated only mianserin 
 (log2FC = 1.57, P = 0.0027). The level of the Cpg16 tran-
script was not significantly altered in any of the analyzed 
brain regions upon drug treatment. The venlafaxine treat-
ment downregulated the expression of the Dcl isoform in 
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the NAc  (log2FC = − 0.74, P = 0.078). However, the level 
of the Dcl transcript in the PFCx increased in response 
to the mianserin treatment  (log2FC = 0.46, P = 0.0009). 
The expression of the full-length Dclk1 transcript (ENS-
MUST00000054237) was below the level of detection in 
the NAc, and no significant changes were observed in the 
PFCx. The expression of the intron-retained isoform (RI) 
was substantially upregulated by mianserin  (log2FC = 0.9, 
P = 2.8 × 10−6) and risperidone  (log2FC = 0.49, P = 0.002) 
in the NAc and by mianserin  (log2FC = 0.69, P = 0.0003) 
in the PFCx.
Furthermore, when we mapped individual reads to the 
Dclk1 locus, a considerable number of fragments did not 
match known transcripts and corresponded to a frag-
ment annotated as an intronic region (Fig. 4b, red arrow). 
Exon-level analysis of the data suggested the presence 
of a novel transcript, referred to as Dclk1-m, with an 
alternative transcription start site (first exon), termina-
tion codon (last exon) and a sequence corresponding to 
the sixth intron of the canonical Dclk1 transcript (ENS-
MUST00000054237). The detected retention of intron 
6 is unlikely to correspond to an unspliced pre-mRNA. 
Fig. 2 Drug‑induced alterations in gene expression in the mouse NAc and PFCx. Hierarchical clustering analysis of drug‑induced changes in gene 
transcript levels. RNA‑seq results are shown as a heat map and include 113 transcripts with a genome‑wide significance (FDR < 0.001 two‑way 
ANOVA of the treatment factor). Transcriptional events regulated by the drugs are listed in Additional file 3. Colored rectangles represent the 
transcript abundance 2 h after the injection of the drug indicated above the rectangle (HAL: haloperidol; RIS: risperidone; MIA: mianserin; VEN: 
venlafaxine; MET: methamphetamine; KET: ketamine and SAL: saline control). Representative genes are presented on the right. The intensity of the 
color is proportional to the standardized value (z‑score between − 2 and 2) of each RNA‑seq measurement, as indicated on the bar below the heat 
map. Clustering was performed using Euclidean distances. Major branches from the clusters of drug‑responsive changes are labeled 1–4
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The level of intron coverage calculated as the median 
read coverage for each position at each intron was signifi-
cantly higher (P = 0.002) for this intron compared with 
that of other introns (Fig. 4a).
Based on the frequency of the sequence reads cor-
responding to the Dclk1-m variant, the expression of 
this isoform was upregulated in the PFCx by the mian-
serin treatment  (log2FC = 0.679, P = 0.0000253) and in 
Fig. 3 RNA‑seq–based changes in levels of Dclk1 transcripts. Bar graphs show  log2‑fold changes compared with those of the saline control. Bars 
indicate the S.E.M., *P < 0.01, **P < 0.001, ***P < 0.0001, one‑way ANOVA of the drug factor
Fig. 4 Identification of novel drug‑regulated isoform of Dclk1. a Transcript levels measured as the median read coverage from each particular 
intronic region. The signal from the consecutive Dclk1 introns are presented on the x‑axis. b Representative RNA‑seq tracks showing the 
transcriptional profile of the Dclk1 locus. The transcripts are annotated based on the Ensembl database, as well as the novel drug‑regulated isoform 
Dclk1‑m and are presented below. The arrow indicates drug‑induced regulation of the transcript level
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the NAc by mianserin and risperidone  (log2FC = 0.862, 
P = 3.8 × 10−8;  log2FC = 0.542, P = 0.00079, respec-
tively; Fig.  5 and Additional file  5: Figure S5). Notably, 
the ILMN_1259689 probe shown in Fig.  1 hybridized 
with Dclk1-m. In conclusion, next-generation sequenc-
ing analysis confirmed the drug-specific induction of 
transcription from the Dclk1 locus and showed that 
psychotropic drugs affected the transcription of a short 
region close to the sequence encoding the serine-proline 
rich domain. Most importantly, changes in transcription 
might actually represent a novel transcript, Dclk1-m.
Validation of drug‑induced expression of Dclk1 isoforms
We designed a series of isoform-specific probes for qPCR 
to confirm which of the transcripts exhibited increased 
expression in response to drug treatments. The analysis 
was performed on a new set of samples obtained from 
mice euthanized 2 h after the i.p. injection of mianserin 
(20 mg/kg), risperidone (0.5 mg/kg), haloperidol (1 mg/
kg) or saline (n = 8). Five fluorescent probe assays were 
used to analyze changes in the expression of Dclk1 tran-
scripts; two of the assays were specifically designed to 
detect the isoform containing the retained intron (Fig. 6, 
5′ region of intron 6 and 3′ region of intron 6).
The mianserin treatment increased the levels of tran-
scripts containing intron 6 in the NAc (approximately 
1.5-fold). The level of Cpg16 was slightly decreased, 
whereas levels of Dcl/Carp were not different from those 
of the saline-treated control group. Risperidone signifi-
cantly induced the expression of the Dclk1/Dcl isoform 
(approximately 1.2-fold), as well as transcripts contain-
ing intron 6 (approximately 1.6- to 2.1-fold). The halop-
eridol treatment had no effect on the expression of Dclk1 
isoforms in the NAc. In the PFCx, the mianserin treat-
ment upregulated the expression of Dcl/Carp isoforms 
(1.5-fold), as well as transcripts containing intron 6 (more 
than twofold). Risperidone did not regulate the expres-
sion of Dclk1 isoforms in the PFCx. The haloperidol 
treatment slightly decreased the expression of a variant 
containing part of intron 6 in the PFCx (Fig. 6 and Addi-
tional file 6: Figure S6).
We also performed two additional experiments and 
measured the transcript levels 4 h after a single treatment 
and 2  h after 5  days of treatment. The mianserin treat-
ment significantly increased levels of Dclk1-m in the 
NAc. The effect of mianserin on Dclk1 expression was 
not detected 5 days after repeated drug treatment (Addi-
tional file 7: Figure S7). Together, these data confirm that 
Dclk1-m expression is acutely increased in response 
to the mianserin treatment. Levels of other Dclk1 tran-
scripts were not increased in response to the mianserin 
treatment, with the possible exception of Carp.
Functional features of the newly detected Dclk1 variant
Finally, we used mass spectrometry to determine 
whether protein products of the Dclk1-m transcript were 
detected. Dclk1-m and Carp sequences overlap on the 5′ 
side of the putative protein-coding sequences; only the 
C-termini differ. Both sequences include the proline- 
and serine-rich (SP-rich) region that interacts with other 
proteins. Mass spectrometry analysis of the SDS-PAGE-
purified protein fraction with a molecular weight less 
than 10 kDa confirmed the presence of the SP-rich frag-
ment (Fig.  7). Shotgun LC–MS/MS analysis, performed 
in addition to PRM, did not show a presence of other 
fragments derived from either CARP or DCLK1-M. 
Thus, we were only able to conclude that either or both 
the DCLK1-M and CARP proteins are translated.
Discussion
Our results reveal the existence of a novel Dclk1 iso-
form (Dclk1-m), the expression of which is induced 
in the nucleus accumbens and prefrontal cortex of the 
brain after treatment with psychotropic drugs that 
affect 5HT2A/C receptor signaling (i.e., mianserin and 
risperidone). It should be noted here that these drug-
related effects are relatively unspecific in pharmacologi-
cal action, and transcription might be triggered by the 
activity of more than one type of neuronal receptors. 
Notably, Dclk1-m is the main, if not exclusive Dclk1 tran-
script whose expression appears to be regulated by drugs. 
At present, we were not able to unequivocally establish 
whether Dclk1-m is translated; we were only able to 
confirm that protein products of Dclk1-m or Carp were 
present.
The identification of Dclk1-m revises and extends 
observations from our previous reports, where we 
detected an increase in Dclk1 expression after treatment 
with mianserin and risperidone [2, 3, 13]. However, due 
Fig. 5 Drug‑induced changes in the expression of a novel Dclk1 
isoform (Dclk1‑m). Changes in the level of Dclk1‑m measured by 
RNA‑seq. The results are shown as  log2‑fold changes compared 
with those of the saline control. Bars indicate S.E.Ms, **P < 0.001, 
***P < 0.0001, one‑way ANOVA of the drug factor
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to limitations regarding the array methodology used in 
our previous study, we were not able to discern exactly 
which transcripts were induced by drug actions in many 
cases. The array probes used in gene expression arrays 
may actually be detecting Dclk1-m, Carp and Dcl. Fur-
thermore, we postulate that other previous reports may 
have been reporting changes in Dclk1-m expression, 
as well. We concluded that drug treatment regulated 
the expression of brain-specific isoforms of Dclk1 with 
an alternatively spliced last exon—either Dcl or Carp. 
In-depth analysis of RNA-seq data revealed that psy-
chotropic drug treatments induced the expression of a 
Fig. 6 Validation of mianserin‑induced changes in Dclk1 expression. Changes in mRNA levels were measured 2 h after administration of mianserin 
or saline. qPCR analyses were performed using samples from an independent biological experiment (n = 8). TaqMan probes distinguished the 
following specific transcriptional variants: qPCR “probe 1” spans the exon junction of exons 4 and 5 of the Dclk1 (ENSMUST00000054237) transcript, 
qPCR “probe 2” spans exons 6 and 7 in Dcl (ENSMUST00000167204), qPCR “probe 3” spans 5′ part of intron 6 of Dclk1 (ENSMUST00000054237), and 
qPCR “probe 4” spans 3′ part of intron 6 of Dclk1 (ENSMUST00000054237), qPCR “probe 5” spans exons 13 and 14 of Cpg16 (ENSMUST00000198437). 
The locations of TaqMan probes used for qPCR are labeled (probes 1–5). Bars indicate the S.E.M, ***P < 0.001, one‑way ANOVA of the drug factor
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previously unannotated transcript. The expression of this 
transcript was upregulated in the NAc by mianserin and 
risperidone and in the PFCx by mianserin. The Dclk1-
m isoform contains a retained intron covering the mid-
dle part of the Dclk1 locus. Thus, this intron is a region 
of the gene important for the mechanisms of action of 
those drugs. Both mianserin and risperidone are potent 
antagonists of 5-HT2a receptors, which might mediate 
the effect on Dclk1-m transcription. Moreover, the addi-
tion of mianserin to typical antipsychotics improves their 
therapeutic efficacy in patients with schizophrenia [22]. 
Polymorphisms in the Dclk1 gene are associated with the 
development of schizophrenia. Thus, the altered func-
tion of the Dclk1 gene may be involved in both the eti-
ology and treatment of this psychopathology. From our 
results, we can’t ascertain whether the increase in Dclk1 
isoform is sufficient to produce the therapeutic effects of 
the drugs. It is likely a more complex phenomenon and 
no single gene or transcript is solely responsible for the 
therapeutic effect.
The Dclk1 gene has a complex structure and comprises 
at least 15 known transcriptional variants. Although 
Dclk1 was first described as a brain-specific gene, the 
roles of Dclk1 outside the nervous system have recently 
been the main area of study. Dclk1 is expressed in a vari-
ety of cancer cells [23], with a functional role in tumor 
growth and progression. However, its general role in car-
cinogenesis and clinical significance as a potential diag-
nostic marker remain unclear [24]. The present analysis 
reveals the brain-region-specific regulation of the expres-
sion of Dclk1 isoforms in response to treatments with 
various classes of psychotropic drugs. A comparative 
meta-analysis of drug-induced Dclk1 expression pro-
files is difficult to perform due to the use of different 
experimental designs (organism, time and tissue selec-
tion) and methodologies. To our knowledge, this study 
is the first to show that Dclk1 expression is regulated 
at the single-exon level. In general, our results are con-
sistent with previous findings and complement them in 
many ways. The short, the Dclk1 transcript Carp (also 
Fig. 7 LC–MS/MS detection of CARP/DCLK1‑M‑derived peptide. a A schematic representation of the Carp and Dclk1‑m transcripts and their 
putative peptide products. Colored boxes mark exons. Peptides were digested with the endoproteinase LysC, which cleaves peptide bonds at the 
carboxyl side of lysine residues (marked red). The fragment corresponding to the SPSPSPTSPGSLRK peptide is marked with a box. b Detection of the 
SPSPSPTSPGSLRK peptide. The panels show (from the left): signal for potential contamination with light peptide checked in heavy peptide sample, 
signal for heavy‑labeled peptide spiked into the experimental sample, signal for endogenous (light) peptide in a sample derived from the murine 
striatum. Colored peaks correspond to peptide fragment ions. Please note the different scales on the y‑axes
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known as Ania-4) is considered an immediate early gene 
(IEG). The expression of this variant increases in striatal 
neurons within minutes of dopamine receptor D1 (D1) 
stimulation [25]. In the hippocampus, the Carp mRNA 
was upregulated following kainate-elicited seizures [9], 
adrenalectomy [26], brain-derived neurotrophic factor-
induced long-term potentiation [27] and repeated expo-
sures to glutamate in hippocampal slice cultures [28]. We 
only identified one study showing the regulation of Dclk1 
expression by psychotropic drugs; this study reported 
that chronic haloperidol, but not clozapine or olanzap-
ine treatments [29], affect Dclk1 transcription. However, 
based on the reported results, we were not able to dis-
tinguish between Dcl, Carp and Dclk1-m. Based on our 
results, the upregulation of Dclk1-m expression is tran-
sient, likely lasting only hours, and was not detected after 
repeated treatment with mianserin.
Interestingly, Dclk1-m potentially encodes a pro-
tein that includes the serine- and protein-rich peptide. 
Using mass spectrometry, we confirmed the presence of 
small proteins containing the SP-rich domain that were 
potentially derived from CARP or DCLK1-M. There-
fore, the newly identified variant might be translated into 
a protein. The SP-rich domain shared by the CARP and 
DLCK1-M peptides is postulated to be responsible for 
interactions with other proteins. To our knowledge, the 
endogenous CARP peptide has never been identified 
in vivo. This domain is predicted to interact with proteins 
containing the Src homology (SH3) domain [30]. Indeed, 
CARP interacts with the adapter protein growth factor 
receptor-bound 2 (Grb2) that contains the SH3 domain 
in vitro [26]. Grb2 plays a role in the formation of den-
dritic spines, which is critical for synaptic development 
[31] and is implicated in regulating actin cytoskeleton 
dynamics [32] and in Ras-ERK kinase activation [33]. 
Thus, the observed effects on Dclk1-m expression may 
correspond to alterations at the protein level. We were 
not able to unequivocally establish whether Dclk1-m is 
translated, although we did confirm that protein products 
translated from Dclk1-m or Carp were indeed present.
Recent results suggest the involvement of DCLK1 in 
dendrite development, as the depletion of endogenous 
DCLK1 affects the complexity of dendritic branch-
ing and total dendritic length in neurons in  vitro [34]. 
DCLK1 plays a critical role in cargo transport into den-
drites; in particular, DCX domains are required for 
dense-core vesicle (DCV) trafficking that causes den-
dritic growth through the release of peptide neuro-
modulators [35]. Notably, DCLK1 kinase activity is 
not required for its ability to bind and bundle microtu-
bules. One of the C-terminal variants (Cpg16) has also 
been suggested to be a candidate neural plasticity gene 
with a potential role in synaptic remodeling. In  vitro, 
CPG16 autophosphorylates and phosphorylates myelin 
basic protein, but the in  vivo target of CPG16 remains 
unknown. CPG16 may be activated by a PKA-induced 
pathway. CARP was proposed to both modulate kinase 
activity [9] and enhance DCL-induced tubulin polym-
erization [36] in  vitro. The proposed roles in synaptic 
plasticity were based in large part on in silico structural 
analysis. Taken together, the effects of the drug-induced 
expression of Dclk1-m on controlling synaptic dynamics 
might be mediated at multiple molecular levels.
Another interesting observation from our study is the 
expression levels of specific Dclk1 isoforms. Generally, 
isoforms driven by the upstream promoter are expressed 
at high levels in mice during early stages of life (P0–P5), 
whereas downstream promoter-derived transcripts 
are adult-specific [37]. In our study, the most abundant 
isoform in both the NAc and PFCx is Cpg16, which is 
consistent with the literature [6]. Carp was reported to 
be exclusively expressed in adulthood, although some 
reports show that its expression in the mouse brain is 
undetectable under basal conditions but dramatically 
increases upon stimulation [25]. One of the unexpected 
findings from our study is that the full-length Dclk1 iso-
form was detected in PFCx, although it was reported to 
only be expressed during brain development [6, 36]. Dcl 
expression has been reported in specific neuronal cell 
populations and implicated in adult neurogenesis [38, 
39]. We concluded that the expression level of Dclk1 
isoforms might exhibit brain region-specific patterns. 
The number and different proportions of Dclk1 isoforms 
make it very difficult to study in vitro. We aim to evalu-
ate the expression of Dclk1 isoforms in primary cultures 
of neurons and astrocytes [3]. We observed significant 
differences in the levels of Dclk1 isoforms between pri-
mary cultures and brain tissues. Notably, the Cpg16 
isoform was expressed at high levels in vivo but was vir-
tually undetectable in cell cultures. The full-length Dclk1 
transcript was expressed at higher levels in cultured 
neurons than in brain tissues. This finding is not sur-
prising because primary neuronal cultures are derived 
from mouse embryos. Moreover, stimulation of neurons 
with kainic acid (activity-regulated gene expression) and 
astrocytes with dexamethasone (GR-dependent gene 
expression) did not change the expression of any Dclk1 
isoforms. Thus, studies of the mechanisms regulating the 
expression of Dclk1 isoforms in the brain should not be 
conducted in vitro.
Conclusions
In conclusion, we identified a previously unknown Dclk1 
transcript, which is expressed in response to treat-
ment with psychotropic drugs. This study enhances our 
understanding of brain plasticity by revealing that the 
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expression of alternative Dclk1 transcripts is an impor-
tant component of the pharmacological treatment of 
neuropsychiatric disorders. Although further studies will 
allow researchers to determine the precise role of the 
newly discovered Dclk1-m variant, our findings reveal a 
previously unknown molecular mechanism of mianserin 
action. Moreover, our research also emphasizes the need 
to carefully analyze the raw data obtained from high-
throughput gene expression profiling experiments, as 
analyses that are restricted to previously annotated tran-
scripts might provide us with false-positive results, as in 
the case of Dclk1 transcripts. The data reported here may 
also serve as a set of drug-specific transcriptional signa-
tures in the PFCx and NAc.
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Additional file 1. The lists of transcripts and corresponding gene names 
that are altered by drug treatment after one‑way ANOVA in each tissue 
(FDR < 0.0001).
Additional file 2. The charts presenting the distribution of transcripts bio‑
types among the drug‑regulated transcripts in comparison to the entire 
transcriptome of the mouse nucleus accumbens and prefrontal cortex.
Additional file 3. Results from two‑way ANOVA for 113 drug‑responsive 
transcripts (FDR for drug factor < 0.001) are included. For each transcript, a 
fold change over control, p‑value and FDR for drug and tissue factors and 
all the interactions are presented. Table also includes biotypes annota‑
tion and classification using the BioMart interface to the Ensembl gene 
database.
Additional file 4. RNA‑seq results from two‑way ANOVA for all Dclk1 iso‑
forms reported in Ensembl gene database (GRCm38.p5/mm10). For each 
transcript, a fold change over control, p‑value and FDR for drug and tissue 
factors and all the interactions are presented.
Additional file 5. Table summarizing the RNA‑seq re‑analysis for Dclk1 
locus with Dclk1‑m variant added. The first sheet presents the results from 
one‑way ANOVA for NAc, the second sheet for PFCx. For each transcript, a 
fold change over control, p‑value and FDR for drug is presented.
Additional file 6. Changes in mRNA levels were measured 2 h after 
administration of risperidone, haloperidol or saline control. qPCR 
analyses were performed using samples from an independent biological 
experiment (n = 8). TaqMan probes distinguished the following specific 
transcriptional variants: qPCR “probe 1” spans the exon junction of exons 
4 and 5 of the Dclk1 (ENSMUST00000054237) transcript, qPCR “probe 
2” spans exons 6 and 7 in Dcl (ENSMUST00000167204), qPCR “probe 3” 
spans 5′ part of intron 6 of Dclk1 (ENSMUST00000054237), qPCR “probe 4” 
spans 3′ part of intron 6 of Dclk1 (ENSMUST00000054237), qPCR “probe 5” 
spans exons 13 and 14 of Cpg16 (ENSMUST00000198437). The locations 
of TaqMan probes used for qPCR are labeled in Figure 6. Bars indicate the 
S.E.M., *P < 0.01, one‑way ANOVA of the drug factor.
Additional file 7. Changes in mRNA levels were measured (A) 4 h after 
administration of mianserin or saline control (B) 2 h after 5 days of treat‑
ment with mianserin or saline. qPCR analyses were performed using 
samples from an independent biological experiment (n = 4). The locations 
of TaqMan probes used for qPCR are labeled in Figure 6. Bars indicate the 
S.E.M., **P < 0.001, one‑way ANOVA of the drug factor.
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